Published in Medical Imaging Business Week, February 22nd, 2007
This trend article about Massachusetts General Hospital, Boston, U.S., is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Research findings, "Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer," are discussed in a new report. According to recent research from the United States, "Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.